Format

Send to

Choose Destination
Pharmacogenomics. 2017 May;18(7):639-650. doi: 10.2217/pgs-2017-0003. Epub 2017 May 8.

Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

Author information

1
INSERM UMR1178, Team (Depression & Antidepressants), Faculté de Médecine Paris-Sud, Univ. Paris-Sud, Le Kremlin Bicêtre, France.
2
Service de Psychiatrie, Hôpital Bicêtre, Groupe Hospitalier Paris Sud, AP-HP, Le Kremlin Bicêtre, France.
3
Centre de Recherche Clinique (CRC), Hôpital Bicêtre, Groupe Hospitalier Paris Sud, AP-HP, Le Kremlin Bicêtre, France.
4
Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, Groupe Hospitalier Paris Sud, AP-HP, Le Kremlin Bicêtre, France.
5
Centre de Ressources Biologiques, CRB Paris-Sud, Hôpital Bicêtre, Groupe Hospitalier Paris Sud, AP-HP, Le Kremlin Bicêtre, France.

Abstract

AIM:

The antidepressant venlafaxine (VEN) is metabolized by CYP2D6 and CYP2C19. The aim of this study was to assess the relevance of generalizing to daily practice the genotyping of CYP2D6 and CYP2C19 to predict VEN efficacy in depressed patients treated in psychiatric settings.

PATIENTS & METHODS:

This study was nested in a naturalistic cohort, with 206 patients requiring a new antidepressant treatment and genotyped for CYP2D6 *3, *4, *5 del, *6, *2xN, *10, *41 and CYP2C19 *2, *3, *4, *5, *17 alleles.

RESULTS:

CYP2D6 and CYP2C19 phenotypes were associated neither with the Hamilton depression rating scale score improvement, nor with response and remission.

CONCLUSION:

Routine CYP2D6 and CYP2C19 genotyping cannot be recommended to predict VEN efficacy in depressed patients treated in psychiatry settings.

KEYWORDS:

antidepressants; pharmacogenetics; venlafaxine

PMID:
28480819
DOI:
10.2217/pgs-2017-0003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center